Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972264 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of VDPHL01 in Males With AGA
A Phase 3 study of Androgenetic Alopecia and AGA, sponsored by Veradermics.
- Active
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT06972264: Active Phase 3 study of Androgenetic Alopecia and AGA, sponsored by Veradermics.
NCT06972264 is a Phase 3 study of Androgenetic Alopecia and AGA that is active but no longer recruiting, run by Veradermics. The registered enrollment target is 480 participants, above the 135-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (256% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972264, a Phase 3 study of Androgenetic Alopecia and AGA, is active but no longer recruiting, sponsored by Veradermics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Primary Outcome
Change from baseline in non-vellus TAHC using digital image analysis at Month 6.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VDPHL01
Study Locations (20)
Florida
- Site 71 - Boca Raton
- Site 86 - Coral Gables
- Site 62 - Coral Gables
- Site 99 - Miami
- Site 54 - Ocala
- Site 96 - Tamarac
California
- Site 69 - Encino
- Site 64 - Manhattan Beach
- Site 93 - Northridge
- Site 66 - Santa Monica
- Site 94 - Thousand Oaks
Alabama
- Site 73 - Birmingham
- Site 89 - Birmingham
Indiana
- Site 53 - Clarksville
- Site 55 - Plainfield
Arizona
- Site 77 - Phoenix
Georgia
- Site 90 - Sandy Springs
Illinois
- Site 61 - Chicago
Kansas
- Site 79 - Leawood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What the registry record for NCT06972264 still lists
NCT06972264 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 135-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (256% higher).
The record links to 3 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06972264 names 20 study sites across 9 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06972264 about?
NCT06972264 is a clinical study titled "Safety and Efficacy of VDPHL01 in Males With AGA". This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an inve...
What is the current status of trial NCT06972264?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-03-11. Estimated completion is 2027-07.
What conditions does trial NCT06972264 study?
This clinical trial studies the following conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness.
What interventions are being tested in trial NCT06972264?
The interventions under investigation include: Placebo (DRUG), VDPHL01 (DRUG).
Who is sponsoring clinical trial NCT06972264?
This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972264 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06972264's enrollment target sits among peer trials
480 2nd of 16 higher than 14 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
COMPLETED · Phase 3
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI